Table 5 Logistic regression analyses of genetic variations associated with high-level resistance to cefuroxime, levofloxacin, and trimethoprim-sulfamethoxazole in NTHi

Cefuroxime

 HI_1132 (ftsI)

  1070G > A (Ser357Asn)

3.600 (0.322 – 40.233)

0.298

  1594A > T (Thr532Ser)

30.000 (2.037 – 441.839)

0.013

  1669 T > C (Tyr557His)

3.23E09 (0.000 – 0.000)

0.998

 HI_1655 (lpoA)

  453G > C (Met151Ile)

3.55E10 (0.000 – 0.000)

0.999

Levofloxacin

 HI_1264 (gyrA)

  251C > T (Ser84Phe)

6.417 (0.999 – 41.212)

0.050

  263A > G (Asp88Gly)

10.286 (1.018 – 103.948)

0.048

  1299G > T (Glu433Asp)

8.800 (1.349 – 57.426)

0.023

  1414A > G (Ile472Val)

5.333 (0.968 – 29.393)

0.055

  2220 T > A (Asp740Glu)

19.200 (1.876 – 196.539)

0.013

 HI_0567 (gyrB)

  1817C > T (Ala606Val)

4.714 (0.734 – 30.278)

0.102

  2174C > T (Ala725Val)

8.800 (1.349 – 57.426)

0.023

 HI_1529 (parC)

  59A > G (Lys20Arg)

40.000 (3.579 – 477.034)

0.003

  251G > T (Ser84Ile)

7.500 (1.307 – 43.028)

0.024

  1601G > A (Ser534Asn)

7.500 (0.733 – 76.773)

0.090

 HI_1528 (parE)

  434G > A (Ser145Asn)

14.000 (1.385 – 141.485)

0.025

  parC-parE intergenic region

  n.1600250A > C

40.000 (3.579 – 477.034)

0.003

Trimethoprim-sulfamethoxazole

 HI_0899 (folA)

  38A > G (Asn13Ser)

3.77E9 (0.000 – 0.000)

0.999

  63G > A (Met21Ile)

1.364 (0.188 – 9.912)

0.759

  200T > C (Leu67Pro)

1.867 (0.392 – 8.894)

0.433

  250A > T (Asn84Tyr)

1.050 (0.220 – 5.003)

0.951

  283A > C (Ile95Leu)

6.000 (0.919 – 39.185)

0.061

  319A > C (Lys107Gln)

5.133 (0.922 – 28.570)

0.062